Avoidance of apoptotic death via a hyperploid salvage survival pathway after platinum treatment in high grade serous carcinoma cell line models.
apoptosis
cell cycle checkpoint
hyperploid genome
ovarian cancer
platinum chemotherapy
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
19 Nov 2019
19 Nov 2019
Historique:
received:
27
05
2019
accepted:
26
10
2019
entrez:
6
12
2019
pubmed:
6
12
2019
medline:
6
12
2019
Statut:
epublish
Résumé
The alkylating agent platinum is first-line chemotherapy treatment for high-grade serous carcinomas (HGSC) of tubal-ovarian origin. Platinum compounds cause DNA damage and induce apoptotic cell death in the bulk tumor population. However, subpopulations of tumor cells may exhibit diverging behaviors from the bulk tumor due to an alternate stress response that diverts tumor cells from apoptotic death. In this study, we identified a salvage survival pathway in which G2-arrested tumor cells bypassed apoptosis and progressed through aberrant mitotic events to then emerge as a distinct subpopulation of viable large hyperploid cells but with uncertain long-term propagation potential. Platinum-induced large hyperploid cells were flow sorted and showed rare regrowth capacity as compared to their more proficiently regenerating non-hyperploid counterparts. However, detailed time-lapse microscopy provided direct evidence that these hyperploid cells were mitotically active and could divide successfully to produce viable daughter cells. The
Identifiants
pubmed: 31803363
doi: 10.18632/oncotarget.27330
pii: 27330
pmc: PMC6877103
doi:
Types de publication
Journal Article
Langues
eng
Pagination
6691-6712Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST None.
Références
Nature. 2012 Jan 18;481(7381):287-94
pubmed: 22258607
Mol Cell Oncol. 2015 Oct 06;3(2):e1088503
pubmed: 27308610
Oncogene. 2004 Apr 12;23(16):2825-37
pubmed: 15077146
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
Cell Death Dis. 2014 May 29;5:e1257
pubmed: 24874729
Nat Rev Cancer. 2015 Nov;15(11):668-79
pubmed: 26493647
Nat Rev Cancer. 2012 Dec;12(12):801-17
pubmed: 23175119
Biol Cell. 2016 May;108(5):127-48
pubmed: 26871414
J Clin Pathol. 2008 May;61(5):652-7
pubmed: 18006668
Mol Cancer Ther. 2015 Sep;14(9):2004-13
pubmed: 26141948
Hum Pathol. 2007 Jun;38(6):926-34
pubmed: 17397905
Am J Respir Cell Mol Biol. 1994 Jan;10(1):38-47
pubmed: 7507342
Cancer Res. 1988 Nov 1;48(21):6166-72
pubmed: 3167863
Int J Mol Sci. 2017 Nov 06;18(11):
pubmed: 29113112
Oncogene. 2005 Jul 14;24(30):4765-77
pubmed: 15870702
J Clin Pathol. 2002 Jan;55(1):27-31
pubmed: 11825920
Mol Biol Cell. 2014 Sep 15;25(18):2677-81
pubmed: 25213191
Sci Rep. 2017 Dec 1;7(1):16762
pubmed: 29196757
Genes Dev. 2000 Jun 15;14(12):1448-59
pubmed: 10859164
Drug Resist Updat. 2001 Oct;4(5):303-13
pubmed: 11991684
Curr Biol. 2006 Jun 20;16(12):1194-200
pubmed: 16782009
Br J Clin Pharmacol. 2013 Sep;76(3):358-69
pubmed: 23593991
Cancer Res. 2011 Jul 1;71(13):4608-16
pubmed: 21712408
Cancer Res. 1983 Nov;43(11):5379-89
pubmed: 6604576
Cell Death Dis. 2010;1:e25
pubmed: 21364633
Int J Cancer. 2014 Mar 1;134(5):1013-23
pubmed: 23613359
Nat Protoc. 2015 Feb;10(2):334-48
pubmed: 25633629
Am J Physiol. 1993 Aug;265(2 Pt 1):C477-84
pubmed: 8396328
Mol Cell Oncol. 2015 Feb 23;2(4):e1012976
pubmed: 27308506
BMC Cancer. 2012 Aug 29;12:379
pubmed: 22931248
J Natl Cancer Inst. 1990 May 2;82(9):749-55
pubmed: 1691303
Nat Rev Mol Cell Biol. 2011 Jun;12(6):385-92
pubmed: 21527953
Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2415-20
pubmed: 18272492
Cell Cycle. 2010 Jul 15;9(14):2823-9
pubmed: 20686359
Eur J Pharmacol. 2014 Oct 5;740:364-78
pubmed: 25058905
Mutagenesis. 1998 Mar;13(2):193-8
pubmed: 9568594
Cancer Res. 1988 Aug 15;48(16):4484-8
pubmed: 3395999